Design, Synthesis, Molecular Modeling Studies and Biological Evaluation of N′-Arylidene-6-(benzyloxy)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide Derivatives as Novel Anti-HCV Agents

Sayyed Mohammad Ismaeil Mahboubi Rabbani, Rouhollah Vahabpour, Zahra Hajimahdi* and Afshin Zarghi*

*Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Department of Medical Lab Technology, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

HCV-induced hepatitis is one of the most debilitating diseases. The limited number of anti-HCV drugs and drug-resistance necessitate developing of new scaffolds with different mode of actions. HCV non-structural protein 5B (NS5B) is an attractive target for development of novel inhibitors of HCV replication. In this paper, new N′-arylidene-6-(benzyloxy)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide derivatives were designed based on the pharmacophores of HCV NS5B active site binding inhibitors. Designed compounds were synthesized and evaluated for their inhibitory activities in a cell-based HCV replicon system assay. Among tested compounds, compounds 18 and 20 were found to be the most active (EC₅₀ = 35 and 70 µM, respectively) with good selectivity index (SI > 2) in the corresponding series. Molecular modeling studies showed that the designed compounds are capable of forming key coordination with the two magnesium ions as well as interactions with other key residues at the active site of HCV NS5B.

Keywords: Synthesis, Design, 4-Oxo-1,4-dihydroquinoline-3-carbohydrazide, HCV, NS5B polymerase, Molecular modeling studies.

Introduction

Hepatitis C caused by the hepatitis C virus (HCV) has been considered as a leading cause for liver fibrosis, cirrhosis, and hepatocellular carcinoma (1, 2). According to the world health organization (WHO) report, chronic HCV infection has been estimated to affect about 71 million individuals worldwide (3). Prior to 2011, a combination of pegylated interferon alpha and ribavirin was used for HCV therapy, which sometimes caused severe adverse reactions, and was poorly tolerated (4). Currently, the treatment for HCV chronic infection consists of the addition of direct-acting antiviral drugs (DAAs) to the ribavirin regimen with or without pegylated interferon (5, 6). DAAs specifically target essential proteins in HCV life cycle including NS3 protease, NS5A serine protease, and NS5B RNA dependent RNA polymerase (7). In recent years, extensive efforts have been focused on discovery of direct-acting antiviral agents (8, 9). However, the emergence of drug resistance due to mutation of virus necessitate developing of new anti-HCV agents with different mode of actions and structures. Non-structural protein 5B (NS5B) is a RNA-
dependent RNA polymerase that plays a major role in the replicating the viral RNA of HCV. NS5B has no counterpart in human cells, and as a consequence, it is emerged as an attractive therapeutic target. Right-hand-like structure of NS5B polymerase consists of palm, thumb and fingers subdomains. Molecules that bind to and inhibit NS5B polymerase are classified into nucleoside inhibitors (NIs) that target active site and non-nucleoside inhibitors (NNIs) that target one of five allosteric sites referred as the thumb I, thumb II, palm I, palm II and palm-β (10, 11). The NS5B polymerase active site in the top region of the palm subdomain contains two Mg\(^{2+}\) or Mn\(^{2+}\) ions that are kept in their place by conserved residues Asp318, Asp319, and Asp220 (12). The metal ions play a critical role in the formation of the phosphodiester bond between sequential nucleotides (13). Therefore, compounds featuring chelating motif that bind to metal ions can be attributed to NS5B inhibition. This class of inhibitors represents a rare type of active site binding NNIs. Similar to NIs, active site binding NNIs have a high genetic barrier to development of drug resistance, because they bind to the highly conserved active site whereas typical NNIs bind to highly mutable allosteric sites (14-16). Active site binding NNIs inhibitors with a chelating motif generally also bear an aromatic ring directly connected to the chelating core. Since HCV NS5B polymerase shares a similar active site fold to HIV integrase (17), numerous HIV integrase inhibitors including diketoacids (compound 1), 5-hydroxy-pyrimidinones (compound 2), 2-hydroxyisoquinoline-1,3-diones (compound 3), quinolones (compounds 4, 5) have shown potent inhibition against HCV NS5B (Figure 1) (18-23).

Quinolones are among the most privileged scaffolds in medicinal chemistry for designing inhibitors of interesting targets, a notable example being HIV IN inhibitor elvitegravir (24). We have previously introduced some quinolone derivatives based on HIV IN pharmacophores that effectively inhibited HIV-1 in cell culture (compound 6 as an example, Figure 1) (25-33). We expected that these derivatives could

![Figure 1. NS5B polymerase inhibitors (1, 2, 3, 4, 5, and 6) and designed compounds.](image-url)
be HCV inhibitors through targeting NS5B. On this basis, we decided to retain quinolone scaffold as a main core while make changes on substituents on it. Previous studies focused on aromatic substitution on C-6 and C-7 of quinolone scaffold. This prompted us to design analogues with an aromatic substitution on other position of quinolone core. So we introduced arylidenehydrazide fragment at position 3. Since most of quinolone NS5B inhibitor possesses two hydrophobic moieties, we put a O-benzyl group at position C-6 of quinolone core. Combining the two structural modifications into a quinolone scaffold resulted in a new template. In this template, we explored the effect of various substituted benzylidenehydrazides on HCV inhibition.

**Experimental**

**Chemistry**

All chemicals and solvents were purchased from “Merck/Sigma-Aldrich®” company and used directly without purification. Reaction progress was monitored by thin-layer chromatography (TLC) analysis on silicagel 60 F254 plates (Merck), visualized by UV light. Melting points (MP) were determined by the use of a Thomas–Hoover capillary apparatus. Infrared spectra were acquired using a Perkin-Elmer model 1420 spectrophotometer. A Bruker FT-400 MHz instrument (Bruker Biosciences, USA) was used to acquire 1H-NMR spectra. TMS was used as the internal standard and Chloroform-D and DMSO-d6 were used as the solvents. The amounts of coupling constant (J) are estimated in hertz (Hz) and spin multiples are reported as s (singlet), d (doublet), t (triplet), q (quartet) and m (multiplet). The mass spectroscopy experiments were performed by the use of a 6410 Agilent LCMS triple quadrupole mass spectrometer (LC-MS) with an electrospray ionization (ESI) interface. Microanalyses, determined for C and H, were within ± 0.4% of theoretical values.

**Synthesis of N-(4-(benzyloxy) phenyl) acetamide (8)**

To a mixture of acetaminophen (1.0 g, 6.6 mmol) and sodium hydroxide (0.28 g, 6.6 mmol) in methanol (10 mL), benzyl bromide (0.8 mL, 6.6 mmol) was added and stirred for 12 h at room temperature. Then, lots of water was added to the reaction mixture and the precipitate was filtered off and washed up by water and n-hexane give the compound 8. Yield: 98%; mp: 120 °C; IR (KBr): v (cm⁻¹) 3276 (NH), 1656 (C=O), 1400-1600 (aromatic); GC-MS m/z: 241.0 (M, 100).

**Synthesis of diethyl 2-(((4-(benzyloxy)phenyl) amino)methylene)malonate (10)**

Compound 8 (1 g, 4 mmol) was added to a 50% hydro-alcoholic solution of potassium hydroxide (KOH) and the mixture was refluxed for 48 hours. The mixture was poured into ice water and filtered to give the product 9. Yield: 80%; mp: 45 °C; IR (KBr): v (cm⁻¹) 2837 - 3474 (NH₂), 1400-1600 (aromatic); GC-MS m/z: 199.0 (M, 100).

**Synthesis of 6-(benzyloxy)-4-oxo-1,4-dihydroquinoline-3-carboxylate (11)**

A diphenyl ether solution of compound 10 (2 g, 5.4 mmol) containing catalytic 2-chlorobenzoic acid was heated by microwave irradiation (250 °C) for 5 minutes. After cooling, the reaction mixture was filtered and the precipitate was washed with n-hexane and water. Yield: 70%; mp: 210 °C; IR (KBr): v (cm⁻¹) 2725-3241 (NH), 1689 (C=O), 1400-1600 (aromatic); LC-MS (ESI) m/z 324.0 (M+1), 346.1 (M+23).

**Synthesis of 6-(benzyloxy)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (12)**

To a solution of compound 11 (2 g, 3.1 mmol) in absolute ethanol (10 mL), hydrazine hydrate (4 mL, 124 mmol) was added and the mixture was refluxed for 36 hours. After evaporation, the precipitated was filtered off and washed by
water and n-hexane. Yield: 55%; mp: 65 °C; IR (KBr): ʋ (cm⁻¹) 2601-3339 (NH), 1671 (C=O), 1400-1600 (aromatic); LC-MS (ESI) m/z: 310.0 (M+1).

**General procedure for the synthesis of compounds 13-25**

To a solution of compound 12 (0.5 g, 1.6 mmol) in absolute ethanol (10 mL), benzaldehyde derivatives (1.6 mmol) were added and the mixture was refluxed for 36 h. After cooling down to room temperature, the mixture was poured into ice water, and the precipitate was isolated by filtration. Target compounds were obtained by crystallization in ethanol.

**N′-Benzylidene-6-(benzyloxy)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (13)**

Yield: 97%; white powder; mp: 130 °C (decomposed), IR (KBr): ʋ (cm⁻¹) 2725-3223 (NH), 1658 (C=O), 1450-1600 (aromatic C=C); LC-MS (ESI) m/z 398.0 (M+1, 100%); ¹H-NMR (DMSO-d₆, 400 MHz) δ ppm, 5.26 (s, 2H, CH₂), 7.29-7.37 (3H, m, H₃, H₅, H₇-benzyl), 7.40-7.44 (2H, t, H₂-benzyl, J= 8 Hz), 7.50-7.53 (3H, m, H₂, H₅, H₆-benzylidene), 7.71-7.76 (3H, m, H₆-quinoxoline/ H₅, H₆-benzylidene), 7.80-7.84 (2H, m, H₂, H₃-quinoxoline), 8.43 (1H, s, H=C=NH), 8.80 (1H, s, H-quinoxilone), 12.97 (1H, br s, NH-amide), 13.50 (1H, s, NH-quinoxilone); ¹³C-NMR (DMSO-d₆, 100 MHz) δ ppm, 21.53, 70.04, 106.62, 109.49, 122.11, 123.88, 127.59, 128.15, 128.41, 128.79, 128.98, 129.85, 130.00, 132.27, 137.16, 140.18, 143.95, 147.69, 156.22, 162.18, 175.47; Anal. Caled for C₁₅H₁₂N₂O₂: C, 72.53; H, 4.82; N, 10.57. Found: C, 72.42; H, 4.56; N, 10.23.

**6-(Benzyloxy)-N′-(4-fluorobenzylidene)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (15)**

Yield: 85%; white powder; mp: 305 °C (decomposed), IR (KBr): ʋ (cm⁻¹) 2680-3444 (NH), 1662 (C=O), 1450-1600 (aromatic C=C); LC-MS (ESI) m/z 416.2 (M+1, 100%), 853.3 (2M+23, 71%); ¹H-NMR (DMSO-d₆, 400 MHz) δ ppm, 5.26 (2H, s, CH₂), 7.29-7.37 (3H, m, H₃, H₅, H₆-benzylidene), 7.71-7.76 (3H, m, H₆-quinoxilone/ H₅, H₆-benzylidene), 7.80-7.84 (2H, m, H₂, H₃-quinoxilone), 8.43 (1H, s, H=C=NH), 8.80 (1H, s, H-quinoxilone), 12.97 (1H, br s, NH-amide), 13.55 (1H, s, NH-quinoxilone); ¹³C-NMR (DMSO-d₆, 100 MHz) δ ppm 70.04, 106.61, 109.33, 116.20, 116.42, 122.42, 123.75, 127.62, 128.15, 128.40, 128.97, 129.69, 129.74, 131.62, 135.57, 137.18, 144.27, 146.50, 156.16, 162.25, 162.44, 164.71, 175.40; Anal. Caled for C₁₅H₁₄FN₂O₂: C, 69.39; H, 4.37; N, 10.12. Found: C, 69.21; H, 4.12; N, 10.23.

**6-(Benzyloxy)-N′-(4-chlorobenzylidene)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (16)**

Yield: 95%; white powder; mp: 329 °C (decomposed), IR (KBr): ʋ (cm⁻¹) 2676-3312 (NH), 1644 (C=O), 1450-1600 (aromatic C=C); LC-MS (ESI) m/z 432.0 (M+1, 100%), 454.0 (M+23, 36%), 885.0 (2M+23, 18%); ¹H-NMR (DMSO-d₆, 400 MHz) δ ppm, 5.26 (2H, s, CH₂), 7.33-7.37 (1H, t, H₂-benzyl, J= 8 Hz), 7.40-7.44 (2H, t, H₃, H₅-benzyl, J= 8 Hz), 7.49-7.54 (5H,
m, H$_2$-quinolone/H$_2$, H$_2$-chlorobenzylidene/H$_2$, H$_2$-benzyl), 7.71-7.79 (4H, m, H$_2$, H$_2$-chlorobenzylidene/H$_2$, H$_2$-quinolone), 8.43 (1H, s, H-C=N), 8.80 (1H, s, H$_2$-quinolone), 12.98 (1H, br s, NH-amide), 13.49 (1H, s, NH-quinolone). $^{13}$C-NMR (DMSO-d$_6$, 100 MHz) δ ppm 70.06, 106.67, 109.48, 121.66, 124.09, 127.51, 128.16, 128.43, 128.98, 129.21, 129.36, 129.56, 130.50, 133.06, 133.90, 134.42, 134.83, 136.50, 137.10, 143.58, 146.61, 156.35, 161.14, 162.12, 175.62; Anal. Calcd for C$_{12}$H$_8$ClIN$_2$O$_2$: C, 66.75; H, 4.20; N, 9.73. Found: C, 66.56; H, 4.03; N, 9.99.

6-(Benzoxo)-N'-(4-methylbenzylidene)-4-oxo-1,4-dihydroquinoline-3-carboxyrazide (17)

Yield: 98%; white powder; mp: 330 °C (decomposed), IR (KBr): ν 2765-3204 (NH), 1647 (C=O), 1450-1600 (aromatic C=C); LC-MS (ESI) m/z: 412.2 (M+1, 100%), 845.4 (2M+23, 29%); $^1$H-NMR (DMSO-d$_6$, 400 MHz) δ ppm, 2.36 (3H, s, CH$_3$), 5.26 (2H, s, CH$_2$), 7.27-7.29 (2H, d, H$_2$, H$_2$-benzylidene), J = 8 Hz), 7.30-7.37 (1H, t, H$_3$, benzyl, J = 8 Hz), 7.40-7.44 (2H, t, H$_2$, benzyl, J = 8 Hz); 7.48-7.51 (3H, m, H$_2$-quinolone/H$_2$, benzyl), 7.65-7.67 (2H, d, H$_2$, benzylidene, J = 8 Hz), 7.70-7.76 (2H, m, H$_2$, H$_2$-quinolone), 8.36 (1H, s, H-C=N), 8.80 (1H, s, H$_2$-quinolone), 12.98 (1H, br s, NH-amide), 13.52 (1H, s, H$_2$-quinolone). $^{13}$C-NMR (DMSO-d$_6$, 100 MHz) δ ppm 19.0, 70.07, 106.68, 109.48, 116.22, 116.44, 121.86, 124.00, 127.54, 128.16, 128.43, 128.98, 129.70, 129.78, 131.59, 134.73, 137.13, 143.74, 146.72, 156.30, 162.17, 162.28, 164.74, 175.56; Anal. Calcd for C$_{17}$H$_{11}$N$_2$O$_2$: C, 72.98; H, 5.14; N, 10.21. Found: C, 72.65; H, 5.29; N, 10.53.

6-(Benzoxo)-N'-(4-methoxybenzylidene)-4-oxo-1,4-dihydroquinoline-3-carboxyrazide (18)

Yield: 97%; white powder; mp: 154 °C (decomposed), IR (KBr): ν (cm$^{-1}$) 2634-3151 (NH), 1646 (C=O), 1450-1600 (aromatic C=C); LC-MS (ESI) m/z 428.1 (M+1, 100%), 450.1 (M+23, 33%); $^1$H-NMR (DMSO-d$_6$, 400 MHz) δ ppm, 3.82 (3H, s, CH$_3$), 5.22 (2H, s, CH$_2$), 7.01-7.04 (2H, d, H$_2$, benzylidene, J = 8 Hz), 7.32-7.36 (3H, m, H$_3$, H$_4$, H$_5$-benzyl), 7.40-7.44 (2H, t, H$_2$, H$_2$-benzylidene, J = 8 Hz), 7.49-7.51 (d, 2H, H$_2$, benzylidene, J = 8 Hz), 7.60-7.62 (1H, d, H$_2$-quinolone, J = 8 Hz), 7.68-7.74 (2H, m, H$_2$, H$_2$-quinolone, J = 8 Hz), 8.28 (1H, s, H-C=N), 8.76 (1H, s, H$_2$-quinolone), 12.98 (1H, br s, NH-amide), 14.18 (1H, s, NH-quinolone). $^{13}$C-NMR (DMSO-d$_6$, 100 MHz) δ ppm 55.84, 69.87, 114.69, 115.78, 122.66, 128.17, 128.29, 128.91, 129.66, 137.59, 145.17, 157.12, 158.35, 162.08, 175.03; Anal. Calcd for C$_{17}$H$_{11}$N$_2$O$_2$: C, 70.25; H, 4.95; N, 9.83. Found: C, 70.60; H, 4.88; N, 9.60.

6-(Benzoxo)-N'-(3-fluorobenzylidene)-4-oxo-1,4-dihydroquinoline-3-carboxyrazide (19)

Yield: 75%; white powder; mp: 305 °C (decomposed), IR (KBr): ν (cm$^{-1}$) 2670-3254 (NH), 1658 (C=O), 1450-1600 (aromatic C=C); LC-MS (ESI) m/z 416.3 (M+1, 100%), 853.3 (2M+23, 30%); $^1$H-NMR (DMSO-d$_6$, 400 MHz) δ ppm 5.27 (2H, s, CH$_2$), 7.26-7.30 (1H, m, H$_2$-benzyl, J = 8 Hz), 7.34-7.37 (1H, t, H$_2$-fluorobenzylidene, J = 8 Hz), 7.41-7.44 (2H, t, H$_2$, H$_2$-benzyl, J = 8 Hz), 7.50-7.56 (5H, m, H$_2$, H$_2$-benzyl); 8.81 (1H, s, H$_2$-quinolone), 8.45 (1H, s, H-C=N); 8.81 (1H, s, H$_2$-quinolone), 12.98 (1H, br s, NH-amide), 13.56 (1H, s, NH-quinolone); $^{13}$C-NMR (DMSO-d$_6$, 100 MHz) δ ppm 70.08, 106.70, 109.42, 113.44, 113.67, 117.05, 117.25, 121.73, 123.91, 124.08, 127.52, 128.16, 128.43, 128.98, 131.31, 131.39, 134.51, 137.10, 137.49, 137.57, 143.68, 146.57, 156.36, 161.62, 162.23, 164.05, 175.62; Anal. Calcd for C$_{17}$H$_{11}$FN$_2$O$_2$: C, 69.39; H, 4.37; N, 10.12. Found: C, 69.52; H, 4.56; N, 10.30.

6-(Benzoxo)-N'-(2-fluorobenzylidene)-4-oxo-1,4-dihydroquinoline-3-carboxyrazide (20)

Yield: 70%; white powder; mp: 324 °C (decomposed), IR (KBr): ν (cm$^{-1}$) 2581-3527 (NH), 1659 (C=O), 1450-1600 (aromatic C=C); LC-MS (ESI) m/z 416.3 (M+1, 100%), 853.4 (2M+23, 30%); $^1$H-NMR (DMSO-d$_6$, 400 MHz) δ ppm 5.27 (2H, s, CH$_2$), 7.30-7.37 (3H, m, H$_2$, H$_2$-benzyl), 7.41-7.44 (2H, t, H$_2$, H$_2$-benzyl, J = 8 Hz/ J = 4 Hz), 7.48-7.55 (4H,
N′-arylidene-6-(benzyloxy)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide derivatives as novel anti-HCV agents

6-(Benzyloxy)-N′-(3-fluorobenzylidene)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (21)

Yield: 70%; white powder; mp: 291 ºC (decomposed), IR (KBr): v (cm⁻¹) 2620-3396 (N-H), 1690 (C=O), 1450-1600 (aromatic C=C); LC-MS (ESI) m/z 432.3 (M+1, 100%), 454.2 (M+23, 70%); δ ppm 70.01, 106.68, 109.58, 113.44, 113.67, 117.05, 117.25, 121.73, 123.91, 124.09, 124.37, 125.53, 127.78, 128.16, 128.43, 128.99, 130.11, 131.19, 131.39, 134.51, 137.10, 137.47, 146.59, 146.68, 146.75, 156.36, 161.62, 162.23, 164.05, 175.60; Anal. Caled for C₃₁H₂₆FN₂O₄; C, 69.12; H, 4.20; N, 10.34. Found: C, 69.12; H, 4.20; N, 10.33.

6-(Benzyloxy)-N′-(3-methoxybenzylidene)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (22)

Yield: 80%; white powder; mp: 310 ºC (decomposed), IR (KBr): v (cm⁻¹) 2661-3354 (N-H), 1661 (C=O), 1450-1600 (aromatic C=C); LC-MS (ESI) m/z 428.3 (M+1, 100%), 856.4 (M+23, 70%); δ ppm 70.08, 106.68, 109.42, 113.44, 113.67, 117.05, 117.25, 121.73, 123.91, 124.09, 124.37, 125.53, 127.78, 128.16, 128.43, 128.99, 130.11, 131.19, 131.39, 134.51, 137.10, 137.47, 146.59, 146.68, 146.75, 156.36, 161.62, 162.23, 164.05, 175.60; Anal. Caled for C₂₉H₂₄FN₂O₄; C, 69.12; H, 4.20; N, 10.33. Found: C, 69.12; H, 4.20; N, 10.01.

6-(Benzyloxy)-N′-(3-chlorobenzylidene)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (23)

Yield: 85%; white powder; mp: 280 ºC (decomposed), IR (KBr): v (cm⁻¹) 2563-3529 (N-H), 1650 (C=O), 1450-1600 (aromatic C=C); LC-MS (ESI) m/z 412.2 (M+1, 100%), 823 (M+23, 70%); δ ppm 70.01, 106.51, 108.93, 123.34, 126.10, 126.77, 127.75, 128.13, 128.96, 129.85, 131.16, 134.02, 137.29, 137.41, 145.34, 145.54, 155.94, 163.08, 175.14; Anal. Caled for C₃₁H₂₆ClN₂O₄; C, 66.56; H, 4.20; N, 9.73. Found: C, 66.56; H, 4.33; N, 10.01.

6-(Benzyloxy)-N′-(2-methylbenzylidene)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (24)

Yield: 70%; white powder; mp: 280 ºC (decomposed), IR (KBr): v (cm⁻¹) 2665-3424 (N-H), 1663 (C=O), 1450-1600 (aromatic C=C); LC-MS (ESI) m/z 412.2 (M+1, 100%), 856.4 (M+23, 70%); δ ppm 70.01, 106.68, 109.42, 113.44, 113.67, 117.05, 117.25, 121.73, 123.91, 124.09, 124.37, 125.53, 127.78, 128.16, 128.43, 128.99, 130.11, 131.32, 132.91, 134.52, 137.10, 137.47, 143.60, 146.27, 156.33, 162.07, 175.55; Anal. Caled for C₂₉H₂₄N₂O₄; C, 72.98; H, 5.14; N, 10.21. Found: C, 72.74; H, 5.32; N, 10.37.
6-(Benzyloxy)-N′-(2-methoxybenzylidene)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide (25)

Yield: 85%; white powder; mp: 299 °C (decomposed), IR (KBr): υ (cm$^{-1}$) 2481-3164 (NH), 1642 (C=O), 1450-1600 (aromatic C=C); LC-MS (ESI) m/z 428.3 (M+1, 100%), 877.4 (2M+23, 25%); $^1$H-NMR (DMSO-$d_6$, 400 MHz) δ ppm, 3.90 (3H, s, CH$_3$), 5.26 (2H, s, CH$_2$), 7.02-7.06 (1H, t, H$_5$-benzylidene, $J$= 8 Hz), 7.12-7.14 (1H, d, H$_3$-benzylidene, $J$= 8 Hz), 7.34-7.38 (1H, t, H$_4$-benzyl, $J$= 8 Hz), 7.41-7.46 (3H, m, H$_3$, H$_5$-benzyl/ H$_4$-benzylidene), 7.50-7.53 (3H, m, H$_3$, H$_5$-benzyl/ H$_4$-benzylidene, $J$=8 Hz/ $J$=4 Hz), 7.72-7.77 (2H, m, H$_6$, H$_7$-quinolone, $J$=8 Hz/ $J$=4 Hz), 7.86-7.88 (1H, m, H$_5$-quinolone, $J$=8 Hz/ $J$=1 Hz), 8.57 (1H, s, H-C=N); 8.80 (1H, s, H$_2$-quinolone), 12.95 (1H, s, NH-amide), 13.53 (1H, s, NH-quinolone); $^{13}$C-NMR (DMSO-$d_6$, 100 MHz) δ ppm 55.63, 70.07, 106.68, 109.54, 111.94, 116.52, 120.48, 121.67, 124.08, 127.52, 128.17, 128.43, 128.98, 130.35, 134.44, 136.34, 137.11, 143.55, 147.81, 156.35, 159.96, 162.08, 175.62; Anal. Calcd for C$_{25}$H$_{21}$N$_3$O$_4$: C, 70.25; H, 4.95; N, 9.83. Found: C, 70.01; H, 5.97; N, 9.68.

Molecular modeling study

The active compound 21 was selected for docking studies against HCV NS5B. 1GX6 was used for binding mode analysis of NS5B inhibitory activity. All the compounds were built and subsequently optimized using the HyperChem 8.0 software (34). The protein structure was prepared for docking using AutoDock tools 1.5.6 from MGL Tools package (35). Docking was performed by Autodock VINA program (36).

Cell Culture and virus production

Huh7.5 cells originated from hepatocellular carcinoma which has been shown to support efficient HCV replication and production (kindly provided by Rice C) was cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/mL) and streptomycin (100 μg/mL).

The plasmid encoding the full genome of Japonicum Fulminant Hepatitis virus serotype 1 (JFH-1) strain (kindly provided by Wakita T) was used for in-vitro transcription to produce approximately high titer stocks of cell culture-produced virus (HCVcc) as previously described (37).

RT-qPCR assay

Huh7.5 cells were seeded into 48-well plates at a density of 3×10$^5$ cells per well with DMEM containing 10% FBS. After 24 h, huh7.5 cells were infected with HCV viral stock (105 IU/mL) for 3 h, at which point the infection was stopped and each well was washed three times by sterile PBS to removed non-penetrated virions and then the fresh medium was added to each well. Subsequently, the infected cells were treated with newly synthesized compounds at different concentrations and the sofosbuvir (Sigma-Aldrich, USA) as a positive control. After three days inoculation, the supernatant medium was collected and the viral RNA was extracted using viral QIAamp viral RNA mini kit (Qiagen, Düsseldorf, Germany), according to the manufacturer protocol. Then, the amount of HCV replicon RNA was determined using Quantitative RT-PCR assay by hepatitis C virus viral load kit (Gene Proof, Czech Republic, with CE, IVD) according to the manufacturer’s instruction.

The 50% effective concentration (EC50) was determined as the ratio of the normalized...
HCV RNA amount in treated samples relative to the controls (the samples without compound treatment) using GraphPad Prism5.0 software (GraphPad Software, San Diego, CA).

**Cytotoxicity Assay**

The cytotoxicity of compounds to Huh-7.5 cells was measured in parallel with the HCV replication assay based on the cleavage of the yellow tetrazolium salt XTT® (sodium 3-[1 (phenylaminocarbonyl)-3, 4-tetrazolium]-bis(4-methoxy-6-nitro)benzene sulfonic acid) to generate an orange formazan dye by metabolic function of alive and active cells. Cells were treated with various concentrations (500, 250, 100, 25, and 12 μM/mL) of compounds and incubated for 72 hours.

The cell cytotoxicity was determined using XTT proliferation assay kit (Sigma-Aldrich) following the manufacturer’s instructions. The 50% cytotoxic concentration (CC50) was defined as the concentration of compound that reduced cell proliferation by 50%.

**Results and Discussion**

**Chemistry**

Target compounds 13-25 were prepared in good yields (70-98%) from the acetaminophen as a starting material as shown in scheme 1. Starting from benzylation of acetaminophen (7) with benzyl bromide followed by basic hydrolysis of acetamide group gave the O-benzyl aniline (9). The key quinolone intermediate (11) was synthesized via the well-known Gould–Jacobs approach (38). This procedure began with condensation of O-benzyl aniline (9) with ethoxymethylene malonate diethyl ester (EMME) to produce malonate intermediate (10), which upon intramolecular cyclization afforded the ethyl quinolone-3-carboxylate (11). The resulting ester was converted to carbohydrazide analogue (12) via reaction with hydrazine hydrate. N’-Arylidene fragment in target compounds (13-25) were introduced through reaction of carbohydrazide intermediate 12 with substituted benzaldehydes. The structure of the
synthesized compounds was confirmed by IR, $^1$H-NMR, and ESI-MS.

**HCV replicon assay**

Target compounds 13-25 were evaluated in a cell-based viral replication surrogate assay known as the replicon system (39). We hypothesized that our quinolone analogues will inhibit NS5B, likely via binding to the active site. To test this hypothesis, FDA-approved active site binding NI, sofosbuvir, was used as a control compound. In parallel, compounds were also evaluated for their cytotoxic effects in the same cell line to ensure that the activity is completely devoid of cytotoxicity effects. The biological results are expressed as EC$_{50}$, CC$_{50}$ and SI (selectivity index, given by the CC$_{50}$/EC$_{50}$ ratio).

As shown in Table 1, some of the target compounds were found active against HCV with the EC$_{50}$ values in the range from 35 to 120 µM. Furthermore, except for compound 24, all of these active compounds showed SI > 2, rendering them suitable as an inhibitor scaffold for HCV. The anti-HCV assay results revealed a few discernible structure-activity relationship (SAR) trends. First of all, introduction a suitable substituent on the phenyl ring of compounds was found to greatly impact potency as compound 13 with an unsubstituted phenyl was inactive (EC50>200 µM) whereas a number of analogues with substituted phenyl showed significant activity (compounds 20-24). Secondly, the identity of substituent also appeared crucial for inhibition as among active compounds, anti-HCV activity decreased in the following order: Cl > Me > F > OMe > SMe. Thirdly, position of substituent on the phenyl ring influenced the anti-HCV activity as for nearly all substituents, ortho- or meta-position of the phenyl ring was...
tolerated better than para-position. Notably, compound 21 with Cl group in meta-position ($EC_{50} = 35 \mu M$) was proven to be considerably more potent than its para-counterpart ($EC_{50} > 200 \mu M$). In compounds with methyl substitution, changing from ortho- to meta-position increased the both activity ($EC_{50} = 70$ and $45 \mu M$, respectively) and cytotoxicity ($CC_{50} = 160$ and $45 \mu M$, respectively). Regarding the similarity of $EC_{50}$ and $CC_{50}$ of compound 22, it seems that its anti-HCV activity was result of cytotoxicity. Compounds 20 and 24 having, respectively, 2-fluoro and 3-methoxy substitutions displayed similar activities with an $EC_{50} = 120 \mu M$. These differences in activity and toxicity between substituents and their positions may reflect a fundamental change in their binding mode to the protein target or physicochemical properties, although further investigation is required to determine the structure–activity relationships in detail.

Overall, the best activities were observed with 3-chloro (compound 21, $EC_{50} = 35 \mu M$) and 2-methyl (compound 23, $EC_{50} = 70 \mu M$) substituents, suggesting that designed scaffold has the potential for antiviral discovery against HCV. Further optimization may be required to address the potency of compounds.

**Molecular Modeling Study**

Our compounds were designed based on pharmacophore model of NS5B active site inhibitors. Therefore, we generated a docking model to investigate binding modes of designed compounds with NS5B active site. Docking model was generated on the basis of the existing X-ray crystallographic structure of NS5B polymerase complexed with uridine triphosphate (UTP) and divalent metal ions (PDB code: 1GX6) (40). The most active compound
observed in anti-HCV assay, compound 21 was docked into the binding pocket of NS5B active site after the removal of the original UTP. As shown in Figure 4, compound 21 interacted with two Mn$^{2+}$ that are coordinated by active site residues Asp220, Asp318 and Asp319. The Mn$^{2+}$ ions were chelated through two carbonyl groups of quinolone scaffold with the distances of 2.76, 2.37 and 2.42 Å. The O-benzyl moiety of compound 21 was inserted into a hydrophobic pocket in the enzyme consisting of Leu159 and Cys223. Leu159 is an important residue in interaction with the pyrimidine base of co-crystalized UTP. Oxygen atom of O-benzyl formed a hydrogen bond to the side chain of Asp225 with the distance of 3.76 Å, the same residue that is bonded to 2'-hydroxy group of UTP. In addition, NH group of quinolone scaffold formed interactions with side chain of Arg158 and Arg48. An extra hydrophobic bond was found between 3-chlorophenyl group of compound 21 and Cys366. These interactions are in agreement with reported studies on docking of NS5B active site inhibitors (41-43). So anti-HCV activity of synthesized compounds may be due to NS5B inhibition.

Conclusion

In this study, in order to identify new scaffold as anti-HCV agents, we designed and synthesized new N’-aryliden-6-((benzoxo)-4-oxo-1,4-dihydroquinoline-3-carboxyhydrazide derivatives. Results of cell-based HCV replicon assay revealed that several compounds (20, 21, 22, 23, and 24) exhibited moderate to good activity with EC$_{50}$ values ranging from 35 to 120 µM. Molecular modeling studies suggested that the designed compounds might interact with two magnesium ions and other key residues in the NS5B polymerase active site. These results make the designed scaffold a promising starting point for development of more active compounds in future.

References

(1) Bosetti C, Levi F, Lucchini F, Zatonski WA, Negri E and La Vecchia C. Worldwide mortality from cirrhosis: An update to 2002. J. Hepatol. (2007) 46: 827-39.

(2) Modi AA and Liang TJ. Hepatitis C: a clinical review. Oral Dis. (2008) 14: 10-4.

(3) World Health organization, Hepatitis C http://www.who.int/news-room/factsheets/detail/hepatitis-c (Accessed on 28th October 2018).

(4) Neukam K, Macias J, Mira JA and Pineda JA. A review of current anti-HCV treatment regimens and possible future strategies. Expert Opin. Pharmacother. (2009) 10: 417-33.

(5) Alexopoulou A and Karayiannis P. Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. Ann. Gastroenterol. (2015) 28: 55-65.

(6) Lim TR, Tan BH and Mutimer DJ. Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection. Int. J. Antimicrob. Agents. (2014) 43: 17-25.

(7) Zajac M, Muszalska I, Sobczak A, Dadej A, Tomczak S and Jeslna A. Hepatitis C - New drugs and treatment prospects. Eur. J. Med. Chem. (2019) 165: 225-49.

(8) Asselah T and Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int. (2012) 32: 88-102.

(9) Schinazi R, Hafon P, Marcellin P and Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int. (2014) 34: 69-78.

(10) Gerber L, Welzel TM and Zeuzem S. New therapeutic strategies in HCV: polymerase inhibitors. Liver Int. (2013) 33: 85-92.

(11) Shih IH, Vliegen I, Peng B, Yang H, Hebner C, Paeshuyse J, Purstinger G, Fenaux M, Tian Y, Mabery E, Qi X, Bahador G, Paulson M, Lehman LS, Bondy S, Tse W, Reiser H, Lee WA, Schmitz U, Neys J and Zhong W. Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrob. Agents Chemother. (2011) 55: 4196-203.

(12) Bressanelli S, Tomei L, Rey FA and De Francesco R. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J. Virol. (2002) 76: 3482-92.

(13) Appleby TC, Perry JK, Murakami E, Barauskas O, Feng J, Cho A, Fox D, Wetmore DR, McGrath ME and Ray AS. Structural basis for RNA replication by the hepatitis C virus polymerase. Science (2015) 347: 771-5.

(14) Beaulieu P and Tzantrizos Y. Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections. Curr. Opin. Investig. Drugs (2004) 5: 838-50.

(15) Boyce SE, Tirunagari N, Niedziela-Majka A, Perry J, Wong M, Kan E, Lapacan L, Barauskas O, Hung M and Fenaux M. Structural and regulatory elements of HCV NS5B polymerase-β-loop and C-terminal tail are required for activity of allosteric thumb site II inhibitors. PLoS One (2014) 9: e84808.

(16) Powdrill MH, Bernatchez JA and Götte M. Inhibitors of the hepatitis C virus RNA-dependent RNA polymerase
NSB, Viruses (2010) 2: 2169-95.

(17) Hajimahdi Z and Zarghi A. Progress in HIV-1 integrase inhibitors: A review of their chemical structure diversity. Iran. J. Pharm. Res. (2016) 15: 595.

(18) Summa V, Petrocchi A, Matassa VG, Taliani M, Laufer R, De Francesco R, Altamura S and Pace P. HCV NS5B RNA-dependent RNA polymerase inhibitors: from α,γ-diepoxide to 4,5-dihydroxy pyrimidine or 3-methyl-5-hydroxy pyrimidinone carboxylic acids. Design and synthesis. J. Med. Chem. (2004) 47: 5336-9.

(19) Koch U, Atteni B, Malancona S, Colarusso S, Conte I, Di Filippo M, Harper S, Pacini B, Giorni C, Thomas S, Incitti I, Tomel L, De Francesco R, Altamura S, Matassa VG and Narjes F. 2-(2-Thienyl)-5,6-dihydroxy-4-carboxy pyrimidinones as Inhibitors of the Hepatitis C Virus NS5B Polymerase: Discovery, SAR, Modeling, and Mutagenesis. J. Med. Chem. (2006) 49: 1693-705.

(20) Chen YL, Tang J, Kesler MJ, Sham YY, Vince R, Geraghty RJ and Wang Z. The design, synthesis and biological evaluations of C-6 or C-7 substituted 2-hydroxyisoquinoline-1,3-diones as inhibitors of hepatitis C virus. Bioorg. Med. Chem. (2012) 20: 467-79.

(21) Kumar DV, Rai R, Brameld KA, Somoza JR, Rajagopalan R, Janc JW, Xia YM, Torl TL, Shaghati MB and Hu H. Quinolones as HCV NS5B polymerase inhibitors. Bioorg. Med. Chem. Lett. (2011) 21: 82-7.

(22) Chen Y-L, Zacharias J, Vince R, Geraghty RJ and Wang Z. C-6 aryf substituted 4-quinolone-3-carboxylic acids as inhibitors of hepatitis C virus. Bioorg. Med. Chem. (2012) 20: 4790-800.

(23) Cheng Y, Shen J, Peng RZ, Wang GF, Zuo JP and Long YQ. Structure-based optimization and derivatization of 2-substituted quinolone-based non-nucleoside HCV NS5B inhibitors with submicromolar cellular replicon potency. Bioorg. Med. Chem. Lett. (2016) 26: 2900-6.

(24) Daneshotalab M and Ahmed A. Nonclassical biological activities of quinoline derivatives. J. Pharm. Pharm. Sci. (2011) 15: 52-72.

(25) Hajimahdi Z, Ranjbar A, Suratgar AA and Zarghi A. QSAR Study on anti-HIV-1 activity of 4-oxo-1,4-dihydroquinoline and 4-oxo-4H-pyrido[1,2-a] pyrimidine derivatives using SW-MLR, artificial neural network and filtering methods. Iran. J. Pharm. Res. (2015) 14 (Supplement): 69-75.

(26) Hajimahdi Z, Zabihollahi R, Aghasadeghi MR, Ashtiani SH and Zarghi A. Novel quinolone-3-carboxylic acid derivatives as anti-HIV-1 agents: design, synthesis, and biological activities. Med. Chem. Res. (2016) 25: 1861–76.

(27) Hajimahdi Z, Zabihollahi R, Aghasadeghi MR and Zarghi A. Design, synthesis and docking studies of new 4-dihydroxyquinoline-3-carboxyhydrazide derivatives as anti-HIV-1 agents. Drug Res. (2013) 63: 192–7.

(28) Hajimahdi Z, Zarghi A, Zabihollahi R and Aghasadeghi MR. Synthesis, biological evaluation, and molecular modeling studies of new 1,3,4-oxadiazole- and 1,3,4-thiadiazole-substituted 4-oxo-4H-pyrido[1,2-a] pyrimidines as anti-HIV-1 agents. Med. Chem. Res. (2013) 22: 2467–75.

(29) Parizadeh N, Alipour E, Soleymani S, Zabihollahi R, Aghasadeghi MR, Hajimahdi Z and Zarghi A. Synthesis of novel 3-(5-alkyl/aryloxy)-1,3,4-oxadiazol-2-yl)-8-phenylquinolinol-4(1H)-one derivatives as anti-HIV agents. Phosphorus Sulfur Silicon Relat. Elem. (2018) 193: 225-31.

(30) Faghhi K, Safakish M, Zebardast T, Hajimahdi Z and Zarghi A. Molecular Docking and QSAR Study of 2-Benzoxazolinolene, Quinazoline and Diazocoumarin Derivatives as Anti-HIV-1 Agents. Iran. J. Pharm. Res. (2019) 18: 1253-63.

(31) Safakish M, Hajimahdi Z, Zabihollahi R, Aghasadeghi MR, Vahabpour R and Zarghi A. Design, synthesis, and docking studies of new 2-benzoxazolinolene derivatives as anti-HIV-1 agent. Med. Chem. Res. (2017) 26: 2718–26.

(32) Livani ZA, Safakish M, Hajimahdi Z, Soleymani S, Zabihollahi R, Aghasadeghi MR, Alipour E and Zarghi A. Design, synthesis, molecular modeling, in silico ADME studies and anti-HIV-1 assay of new diazoacoumarin derivatives. Iran. J. Pharm. Res. (2018) 17: 65-77.

(33) Hajimahdi Z, Zabihollahi R, Aghasadeghi MR and Zarghi A. Design, Synthesis, Docking Studies and Biological Activities Novel 2,3-Diaryl-4-Quinazolinolone Derivatives as Anti-HIV-1 Agents. Curr. HIV Res. (2019) 17: 214-22.

(34) HyperChem(TM) Professional 8.0, Hypercube, Inc., 1115 NW 4th Street, Gainesville, Florida 32601, USA.

(35) Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK and Olson AJ. Automated Docking Using a Lamarckian Genetic Algorithm and Empirical Binding Free Energy Function. J. Comput. Chem. (1998) 19: 1639-62.

(36) Trott O and Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. (2010) 31: 455-61.

(37) Wakiya T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krüsselich H-G and Mizokami M. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. J. Med. Chem. (2005) 11: 791-6.

(38) Gould Jr. R. and Jacobs W. The synthesis of certain substituted quinolines and 5,6-benzoquinolines. J. Am. Chem. Soc. (1939) 61: 2890-5.

(39) Blight KJ, Kolykhalov AA and Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science (2000) 290: 1972-4.

(40) Bressanelli S, Tomei L, Rey FA and De Francesco R. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J. Virol. (2002) 76: 1284-92.

(41) Deore RR, Chen GS, Chang PT, Chen TR, Lai SY, Chuang MH, Lin JH, Kung FL, Chen CS, Chiuo CT and Chern JW. Discovery of N-arylated-3-hydroxy-4-
Oxo-3,4-dihydroquinazolin-2-carboxamide derivatives as HCV NS5B polymerase inhibitors. *ChemMedChem* (2012) 7: 850-60.

(42) Bhatt A, Gurukumar KR, Basu A, Patel MR, Kaushik-Basu N and Talele TT. Synthesis and SAR optimization of diketo acid pharmacophore for HCV NS5B polymerase inhibition. *Eur. J. Med. Chem.* (2011) 46: 5138-45.

(43) Zhong D, Liu M, Cao Y, Zhu Y, Bian S, Zhou J, Wu F, Ryu KC, Zhou L and Ye D. Discovery of Metal Ions Chelator Quercetin Derivatives with Potent Anti-HCV Activities. *Molecules* (2015) 20: 6978-99.

This article is available online at http://www.ijpr.ir